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Abstract
Background: CFL1 encodes human non-muscle cofilin (n-cofilin), which is an actin-depolymerizing
factor and is essential in cytokinesis, endocytosis, and in the development of all embryonic tissues.
Cfl1 knockout mice exhibit failure of neural tube closure at E10.5 and die in utero. We hypothesized
that genetic variation within the human CFL1 gene may alter the protein's function and result in
defective actin depolymerizing and cellular activity during neural tube closure. Such alterations may
be associated with an increased risk for neural tube defects (NTDs).
Methods: Having re-sequenced the human CFL1 gene and identified five common single nucleotide
polymorphisms (SNPs) in our target population, we investigated whether there existed a possible
association between the genetic variations of the CFL1 gene and risk of spina bifida. Samples were
obtained from a large population-based case-control study in California. Allele association,
genotype association and haplotype association were evaluated in two different ethnicity groups,
non-Hispanic white and Hispanic white.
Results: Homozygosity for the minor alleles of the SNPs studied (rs652021, rs665306, rs667555,
rs4621 and rs11227332) appeared to produce an increased risk for spina bifida. Subjects with the
haplotype composed of all minor alleles (CCGGT) appeared to have increased spina bifida risk (OR
= 1.6, 95% CI: 0.9~2.9), however, this finding is not statistically significant likely due to limited
sample size.
Conclusion: The sequence variation of human CFL1 gene is a genetic modifier for spina bifida risk
in this California population.
Background
Neural tube defects (NTDs) are a group of severe congen-
ital malformations characterized by a failure of neural
tube closure during early embryonic development. NTDs
are complex birth defects with a multi-factorial pattern of
inheritance, requiring both genetic and environmental
factors to contribute to their etiology [1]. The develop-
ment and closure of the neural tube is usually completed
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within 28 days post-conception, in a process that is tightly
regulated yet prone to environmental perturbation [2].
Periconceptional folic acid supplementation has been
repeatedly reported to prevent 50~70% of NTDs [3-5].
Mutations and polymorphisms in folate pathway genes
such as methylenetetrahydrofolate reductase (MTHFR),
methionine synthase (MTR), methionine synthase reduct-
ase (MTRR), and betaine-homocysteine methyltransferase
(BHMT), have been intensively investigated and in some
studies have shown an association with NTD risk [6-9].
However, none of these factors individually contributes
substantially to the population burden of NTDs.
In addition to folate, other developmental mechanisms
have been postulated as contributors to abnormal neural
tube development. Animal models have provided crucial
mechanistic information and possible candidate genes to
explain susceptibility to NTDs [10]. More than 80 genetic
mouse models exhibit NTDs, with new ones emerging
from gene targeting studies and large-scale mutagenesis
screens on a regular basis [2]. A survey of the genes whose
disruption causes NTD indicates multiple key signaling
pathways and cellular functions that are essential for neu-
ral tube closure. One such gene candidate involves non-
muscle cofilin (n-cofilin), an actin-depolymerizing factor.
N-cofilin, encoded by the CFL1 gene, is essential for cyto-
kinesis, endocytosis, and plays a critical role in the devel-
opment of all embryonic tissues. Inactivation of the Cfl1
gene in mice results in embryolethality and failure of neu-
ral tube closure by E10.5 [11]. It has been suggested that
the neural tube closure defects are due to compromised
delamination and migration of neural crest cells in these
animals. In vitro migration assays performed on neural
crest cells from these knockout embryos demonstrated
limited traveling distance, failure of cell polarization, and
a lack of F-actin structures such as fibers, bundles and cor-
tical F-actins [11]. These findings suggest that n-cofilin
regulates cytoskeletal dynamics during neural crest migra-
tion.
The human CFL1  gene (NM_005507), which maps to
chromosome 11q13.1 [12], contains four exons and
encodes an 18.5 kDa phosphoprotein. Human n-cofilin
protein shares 98.8% homology with mouse protein, and
the human CFL1  gene is 92.9% homologous with the
mouse gene. In this study, we re-sequenced the genomic
region on human chromosome 11 which encompasses
the CFL1 gene, and tested the hypothesis that genetic pol-
ymorphisms in human CFL1 gene may modify human
spina bifida risk. This hypothesis was evaluated in a pop-
ulation-based case-control study of infants with spina bif-
ida.
Methods
Subjects
Epidemiological data and biological specimens were
derived from the California Birth Defects Monitoring Pro-
gram, a population-based active surveillance system for
collecting information on infants and fetuses with con-
genital malformations [13]. Program staff collected diag-
nostic and demographic information from multiple
sources of medical records for all live-born and stillborn
fetuses (defined as 20 weeks gestation) and pregnancies
electively or spontaneously terminated. Nearly all struc-
tural anomalies diagnosed within one year of delivery
were ascertained. Overall ascertainment has been esti-
mated as being 97% complete [14].
246 cases (infants with spina bifida) and 336 controls
(non-malformed infants) were included in this study.
Among the 246 cases, 86 (35.0%) were non-Hispanic
white, 128 (52.0%) were Hispanic white, and 32 (13.0%)
were of other ethnicities (African American, Asian, etc.).
Among the 336 controls, 154 (45.8%) were non-Hispanic
white, 113 (33.6%) were Hispanic white, and 69 (20.5%)
were of other ethnicity (African American, Asian, etc.).
These cases and controls were derived from 1983–86 and
1994–95 birth cohorts in selected California counties.
Each case and control infant was linked to its newborn
bloodspot, which served as the source of DNA in our gen-
otyping analyses. All samples were obtained with
approval from the State of California Health and Welfare
Agency Committee for the Protection of Human Subjects.
Genomic DNA was extracted from dried newborn screen-
ing bloodspots using the Puregene DNA Extraction Kit
(Gentra, Minneapolis, MN).
Re-sequencing of CFL1 gene
DNA re-sequencing of CFL1 gene was conducted in a sub-
set of samples (48 cases and 48 controls) in order to iden-
tify all sequence variations of the target genome region.
Primers listed in Table 1 were designed using an online
program, Primer3 [15]. The amplicons generated by the
primers covered the majority of the CFL1  gene locus
(GC11M065378: NCBI build
35:11:65378866~65383462), including the complete
coding region, 5' and 3' un-translated regions, and all
introns. Sequencing analyses were performed using
BigDye Terminator Kit version 3.0 (Applied Biosystems,
Foster City, CA) on an ABI 3730 Genetic Analyzer
(Applied Biosystems, Foster City, CA). Sequencing results
were exported to Sequencher™ software version 4.2.2
(Gene Code Corp., Ann Arbor, MI) for alignment and
multiple comparisons.
Genotyping analysis
Five common single nucleotide polymorphisms (SNPs)
were identified from the re-sequenced CFL1 gene. SNPsBMC Medical Genetics 2007, 8:12 http://www.biomedcentral.com/1471-2350/8/12
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rs652021, rs665306, and rs667555 were genotyped using
TaqMan SNP assays (Assay-on-Demand, Applied Biosys-
tems, Foster City, CA) on an ABI PRISM 7900 Sequence
Detection System (Applied Biosystems, Foster City, CA)
following the manufacturer's instructions. SNPs rs4621
and rs11227332 were genotyped using direct sequencing
analyses. Genotyping assays were performed by labora-
tory technicians who were blinded to the case-control sta-
tus of the samples. Five percent of the samples were
duplicated in order to assess possible genotyping error.
Statistical analysis
Haploview software version 3.3.2 (Daly Lab at the Broad
Institute, Cambridge, MA) was used to perform haplotype
analysis [16]. Haploview software predicts haplotype
based on EM algorithm. Pair-wise Linkage Disequilibrium
(LD) between markers was measured by D' (defined as the
linkage disequilibrium measure, D, divided by the theo-
retical maximum for the observed allele frequencies) and
the correlation coefficient r2. Spina bifida risk was meas-
ured in three ways: allelic association, haplotype associa-
tion, and genotype association. Single SNP allele
association and haplotype association analyses were per-
formed using Haploview software. For each SNP, minor
allele frequency (MAF) and heterozygosity (HET) were
computed, and deviation from Hardy-Weinberg Equilib-
rium (HWE) was tested among control infants. For each
haplotype, counts for case and control association tests
were obtained by summing the fractional likelihoods of
each individual. For example, if an individual was deter-
mined by the EM algorithm to have a 40% likelihood of
haplotype A and 60% likelihood of haplotype B, 0.4 and
0.6 would be added to the counts for A and B respectively.
95% confidence intervals for allele frequencies and haplo-
type frequencies were calculated using an online program,
VassarStats [17]. Spina bifida risks were measured by odds
ratios (ORs). Haplotype-specific odds ratios were com-
puted taking the most common haplotype as reference.
For genotype analysis, ORs were computed for each SNP
by logistic regression models utilizing SAS software (ver-
sion 9.1). Some models were adjusted for race/ethnicity
(defined as non-Hispanic white and Hispanic white).
Results
Five common SNPs were detected through our DNA re-
sequencing effort: rs665306 (intron 1), rs667555 (intron
1), rs4621 (exon 2, synonymous, Asp66Asp), rs652021
(intron 2), and rs11227332 (intron 1). The functional
effects of these polymorphisms were predicted through
FASTSNP (Functional Analysis and Selection Tool for SNP
in Large Scale Association Study)[18] and are listed in
Table 2. rs4621 is a synonymous SNP on exon 2, and the
A allele abolishes a putative exonic splicing enhancer
(ESE) domain. rs11227332 is located in intron 1, and the
G allele of this SNP disrupts a putative transcription factor
(TF) binding site for cAMP-responsive element binding
protein (CREB). SNP rs665306 in intron 1 locates in a
putative binding site for several transcription factors
(TFs), including AP-1, NF-E2 and USF; The nucleotide
change from C to T disrupts the putative USF binding site.
Another SNP in intron 1, rs667555, is in a putative TF
binding site for MZF1, while the less common T allele dis-
rupts the binding. rs652021 is located in intron 2 and has
no known functional effect that can be predicted based on
current knowledge. One novel G->A change, located 2bp
downstream of rs11227332, was observed in 1 spina bif-
ida infant and 1 control infant. Non-synonymous SNPs
listed in the NCBI SNP database (Build 36.1),
rs11550147, rs11550151, rs11550152, rs11550156,
rs11550157, rs11550158 and rs11550160, were not
Table 1: Primer sequences for re-sequencing of CFL1 gene
Primer set name Primer sequence Size of Amplicon (base pair)
CFL1-1 Fw: 5'-GGAAAAGGGAGAGGAACCAG-3'
Rev: 5'-CTGCTACGAGGAGGTCAAGG-3'
538
CFL1-2 Fw: 5'-GGGAACTTGGTCTGCTTCAG-3'
Rev: 5'-CTGCTTTGATTGGCTCCTTC-3'
455
CFL1-3 Fw: 5'-AAGGAGCCAATCAAAGCAGA-3'
Rev: 5'-AAGTCTTCAACGCCAGAGGA-3'
666
CFL1-4 Fw: 5'-ACATCTGGGTTGACCAGGAG-3'
Rev: 5'-AGGGAAGGGGTTGTTGAACT-3'
610
CFL1-5 Fw: 5'-ACCAGATGGGACACAACCTC-3'
Rev: 5'-GTTGTTTTAGGGCGATTCCA-3'
775
CFL1-6 Fw: 5'-GGTCCCTAACCCTGTGGAAT-3'
Rev: 5'-TCTAACGAGCTGCGTTCTCA-3'
320
CFL1-7 Fw: 5'-TGAGAACGCAGCTCGTTAGA-3'
Rev: 5'-GTGCCCTCTCCTTTTCGTTT-3'
695
CFL1-8 Fw: 5'-TTCCGGAAACGAAAAGGAG-3'
Rev: 5'-TGGGCCTACATTTCCCTACA-3'
271
CFL1-9 Fw: 5'-CTGCAGTGCATGTAGGGAAA-3'
Rev: 5'-AACTCGAGAGCTGGGTTCAA-3'
611B
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Table 2: Characteristics of CFL1 SNP markers and allelic association analysis for spina bifida, non-Hispanic White vs. Hispanic White
dbSNP ID Physical 
Location 
(NCBI 
Build 36.1)
Nucleotide 
Change
Location 
in Gene
SNP Function 
Prediction§
Observed 
Heterozygosity§§
HWE p value§§ Minor Allele Frequency 
(95% Confidence Interval)
Allelic 
Association 
P value
NHW HW NHW HW NHW HW NHW HW
SB control SB control
rs652021 10929142 T/C intron 2 no known 
function
0.460 0.438 0.694 0.292 0.412 
(0.341,0.487)
0.315 
(0.265,0.369)
0.395 
(0.337,0.456)
0.446 
(0.383,0.512)
0.054 0.293
rs4621 10929314 A/G exon 2 splicing regulation 
(protein domain 
abolished)
0.453 0.432 0.784 0.248 0.406 
(0.325,0.481)
0.309 
(0.260,0.363)
0.398 
(0.339,0.459)
0.446 
0.381,0.512)
0.061 0.334
rs11227332 10929534 A/G intron 1 intronic enhancer 0.279 0.175 1.000 0.627 0.253 
(0.192, 0.326)
0.163 
(0.123,0.213)
0.169 
(0.128,0.221)
0.107 
(0.072,0.156)
0.042 0.057
rs665306 10929820 C/T intron 1 intronic enhancer 0.459 0.423 0.724 0.184 0.399 
(0.328, 0.474)
0.324 
(0.274,0.380)
0.394 
(0.336,0.455)
0.441 
(0.378,0.507)
0.106 0.339
rs667555 10930357 G/T intron 1 intronic enhancer 0.466 0.435 0.540 0.332 0.386 
(0.315, 0.461)
0.321 
(0.266,0.372)
0.391 
(0.333,0.453)
0.425 
0.361,0.492)
0.161 0.509
§: SNP function prediction performed using FASTSNP (Functional Analysis and Selection Tool for SNP in Large Scale Association Study); §§: Computed in control group
NHW: non-Hispanic white; HW: Hispanic white; HWE: Hardy-Weinberg Equilibrium; SB: spina bifida;BMC Medical Genetics 2007, 8:12 http://www.biomedcentral.com/1471-2350/8/12
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found in our study population. Therefore, these SNPs
were not subjected to our analyses of the case-control
data.
The five common SNPs were genotyped in the case-con-
trol study. Genotyping was successful for 99.6%, 99.2%,
95.1%, 98.0% and 96.7% among cases, and 99.1%,
98.8%, 86.9%, 97.0% and 94.9% among controls, for
rs652021, rs4621, rs11227332, rs665306 and rs667555,
respectively. Missing of genotyping results was due to fail-
ure of PCR amplification caused by limited amount of
DNA. Successful rates between cases and controls were
not significantly different except for SNP rs11227332.
Characteristics of SNP markers genotyped for CFL1 gene
as well as allelic association with spina bifida risk in the
two major subpopulations, non-Hispanic whites and His-
panic whites, are listed in Table 2 and sorted by their phys-
ical location on the chromosome. Among controls, non-
Hispanic whites and Hispanic whites were in Hardy-
Weinberg Equilibrium (HWE) for all SNPs studied. Strong
linkage disequilibria were observed for all markers in both
populations based on the calculation of D' and r2 (Table
3). Among the non-Hispanic whites, SNPs rs652021,
rs4621 and rs11227332 presented significantly higher
minor allele frequencies (MAF) in the spina bifida infants
than in the controls (p < 0.05), with no appreciable differ-
ence between the Hispanic white cases and controls; this
suggests a possible association between these less com-
mon alleles and spina bifida risk among the non-Hispanic
white population.
We performed association analyses between haplotypes
and spina bifida risk in the two major ethnicity groups
using the Haploview program; the results are presented in
Table 4. Haplotypes were estimated based on the EM algo-
rithm. Only haplotypes with frequencies greater than 1%
were included in the analyses. In non-Hispanic white con-
trols, the most common haplotype was TAACG (0.642),
while in Hispanic white controls, the most common hap-
lotype was CGATT (0.441). In both ethnic groups, the
haplotype CGGTT, which is composed of all minor alleles
for the five SNPs, appeared to be associated with a slightly
increased risk for spina bifida (OR = 1.6). We then tested
haplotypes of each two adjacent SNPs. In non-Hispanic
whites, haplotype CG for rs652021-rs4621 (OR = 1.5,
95% CI: 1.0, 2.2) and haplotype GT for rs11227332-
rs665306 (OR = 1.6, 95% CI: 1.0, 2.6) appeared to be
associated with modestly increased risk of spina bifida
compared to wild types TA or AC, respectively. In His-
panic whites, haplotype GT for rs11227332-rs665306
exhibited slightly elevated risk (OR = 1.6, 95% CI: 0.9,
2.9).
We also evaluated the association between individual
CFL1 SNP marker genotypes and spina bifida risk (Table
5) in the overall population, as well as in the two major
ethnic subpopulations, non-Hispanic white and Hispanic
white. Among non-Hispanic whites, homozygotes for the
minor alleles for all SNPs exhibited more than a two-fold
increase in risk for spina bifida. Increases in risk were also
seen in Hispanic whites; however, these increases were
not statistically significant, i.e., consistent with random
variation.
We performed functional prediction using an online pro-
gram,  FASTSNP, which predicts functional impact of
SNPs according to current knowledge. FASTSNP provides
a "risk score" for each SNP based on its putative biological
Table 3: Pairwise LD of CFL1 SNP markers in different ethnicities
nonHispanic White
rs652021 rs4621 rs11227332 rs665306 rs667555
rs652021 -- 0.985 0.335 0.954 0.732
rs4621 1.000 -- 0.342 0.939 0.746
rs11227332 0.879 0.88 -- 0.381 0.391
rs665306 0.984 0.984 0.958 -- 0.744
rs667555 0.856 0.87 0.959 0.869 --
Hispanic White
rs652021 rs4621 rs11227332 rs665306 rs667555
rs652021 -- 0.982 0.093 0.982 0.89
rs4621 1.000 -- 0.095 0.964 0.872
rs11227332 -1.000 -1.000 -- 0.092 0.088
rs665306 1.000 1.000 -1.000 -- 0.888
rs667555 0.980 0.979 -1.000 0.96 --
D' is below the diagonal, r2 is above the diagonalBMC Medical Genetics 2007, 8:12 http://www.biomedcentral.com/1471-2350/8/12
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function. Among the five SNPs we studied, rs4621, which
is a synonymous change located in exon 1, has the highest
"risk score". SNP rs652021 has a risk score of zero, which
means that it has essentially no known functional impact.
Strong linkage disequilibrium (LD) was observed among
the five SNPs in both sub-populations (non-Hispanic
white and Hispanic white) in our study. Therefore, the
observed associations of these SNPs with spina bifida
could be due to the strong LD to the "real" functional var-
iation.
Discussion and conclusion
To our knowledge, this is the first investigation of human
CFL1 gene polymorphisms as risk factors of spina bifida
risk. Infants with the CGGTT haplotype had an increased
spina bifida risk in the two studied ethnic groups. The
observed increases in spina bifida risks indicated a possi-
ble role of actin depolymerizing factor in human neural
tube morphogenesis.
One possible mechanism underlying the observed results
that can be suggested follows. During early embryonic
development, genes that regulate various morphogenetic
activities must function cooperatively for the neural tube
to close properly. Neural crest cell migration is one of
these critical activities [2]. Neural crest cells migrate from
the neural tube to the periphery and give rise to a variety
of cell types. Therefore faulty neural crest cell migration
might interfere with normal neural tube closure. This sug-
gestion is bolstered by observations derived from experi-
mental models. Mammals have at least three highly
conserved genes encoding F-actin polymerizing factors: n-
cofilin [19], m-cofilin (muscle cofilin) [20], and ADF
(actin depolymerizing factor) [21]. Actin depolymeriza-
tion is one of the key activities required for actin-driven
motility [22]. Recently, detailed analysis of n-cofilin func-
tion in mouse embryonic development using gene knock-
out technology suggested that n-cofilin is essential for
neural crest cell migration [11]. Our study, from a popu-
Table 4: Associations between haplotypes and spina bifida risk, non-Hispanic White vs. Hispanic White
Haplotype Freq. (95% CI) § Estimated Haplotype Counts OR 95% CI
Case Control
Non-Hispanic White
TAACG 0.642 (0.588,0.695) 96.7 192.5 ref.
CGGTT 0.161 (0.123,0.206) 38.7 48.4 1.6 0.9, 2.6
CGATT 0.128 (0.094,0.169) 24.1 38.3 1.3 0.7, 2.2
CGATG 0.028 (0.009,0.075) 8.3 3.2 -- --
TAACT 0.024 (0.011,0.047) 1.1 7.3 -- --
Hispanic White
CGATT 0.441 (0.376,0.505) 108.7 98.7 ref.
TAACG 0.414 (0.354,0.483) 96.9 92.8 0.9 0.6, 1.4
CGGTT 0.108 (0.073,0.155) 43.2 24.2 1.6 0.9, 2.9
TAACT 0.023 (0.010,0.051) 3.1 5.2 -- --
Non-Hispanic White
Block 1 rs652021-rs4621
TA 0.683 (0.629,0.733) 99.0 209.0 ref.
CG 0.314 (0.264,0.368) 68.0 96.0 1.5 1.0, 2.2
Block 2 rs11227332-rs665306
AC 0.668 (0.614,0.720) 100.6 201.7 ref.
AT 0.162 (0.124,0.207) 27.2 48.3 1.1 0.7, 1.9
GT 0.165 (0.129,0.213) 41.0 50.4 1.6 1.0, 2.6
Hispanic White
Block 1 rs652021-rs4621
TA 0.442 (0.379,0.508) 100.0 100.0 ref.
CG 0.553 (0.488,0.617) 153.0 125.0 1.2 0.9,1.8
Block 2 rs11227332-rs665306
AT 0.456 (0.394,0.523) 112.1 102.6 ref.
AC 0.438 (0.375,0.503) 100.5 99.0 0.9 0.6, 1.4
GT 0.106 (0.074,0.156) 43.4 24.4 1.6 0.9, 2.9
§ Estimated haplotype frequencies and 95% confidence intervals in control groupBMC Medical Genetics 2007, 8:12 http://www.biomedcentral.com/1471-2350/8/12
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lation perspective, revealed that genetic variations of actin
depolymerizing factor n-cofilin among infants may con-
tribute to the risk of spina bifida.
The strengths of this study include its population-based
ascertainment of cases and controls and its evaluation of
race/ethnicity as a potentially important modifier of risk
in the presence of variant genotypes and haplotypes. Pop-
ulation variation needs to be evaluated in population-
based case control studies of gene-risk association. Haplo-
type association analysis in both sub-populations sug-
gested that haplotype CGGTT, which is comprised of
minor alleles of all five SNPs, conferred an increased risk
of spina bifida. Although not unexpected, it is noteworthy
that the distribution of haplotypes differed between the
two ethnic groups. For example, the frequency of the high
risk haplotype CGGTT in non-Hispanic whites (0.161)
was higher than that in Hispanic whites (0.108). Ordinal
logistic regression analysis revealed that the homozygous
status of minor alleles of all five SNPs were each associ-
ated with a greater than two-fold increase in spina bifida
risk in the non-Hispanic white population. These
increases were also seen in Hispanic whites, even though
they did not reach statistical significance. There is cur-
rently no experimental data on the functional conse-
quences of these variants. We performed functional
prediction using an online program, FASTSNP, which pre-
dicts functional impact of SNPs according to current
knowledge. FASTSNP provides a "risk score" for each SNP
based on its putative biological function. Among the five
SNPs we studied, rs4621, which is a synonymous change
located in exon 1, has the highest "risk score". SNP
rs652021 has a risk score of zero, which means that it has
essentially no known functional impact. Strong linkage
disequilibrium (LD) was observed among the five SNPs in
both sub-populations (non-Hispanic white and Hispanic
white) in our study. Therefore, the observed associations
of these SNPs with spina bifida could be due to the strong
LD to the "real" functional variation.
Our results, although based on multiple tests on small
sample sizes and therefore lowered statistical power, rep-
resent a preliminary step in elucidating the association
between CFL1 gene variations and spina bifida risk. The
haplotype CGGTT, which is composed of minor alleles of
all five SNPs and was commonly found in both major
race/ethnic groups studied, conferred an increased risk of
spina bifida. Combined with existing knowledge about
Table 5: Association between CFL1 genotypes and spina bifida risk: Odds Ratio estimation by Logistic Regression
No. of Control (%) No. of Spina Bifida (%) Crude OR (95% CI) Non-Hispanic White 
OR (95% CI)
Hispanic White OR 
(95%CI)
rs652021
TT 102 (30.6) 55 (22.5) ref Ref ref
TC 154 (46.3) 122 (49.8) 1.5 (0.9, 2.2) 1.1 (0.6, 2.0) 1.8 (0.9, 3.7)
CC 77 (23.1) 68 (27.8) 1.6 (1.0, 2.6) 2.8 (1.2, 6.5) 1.7 (0.8, 3.6)
rs4621
AA 104 (31.3) 57 (23.4) ref Ref ref
AG 151 (45.5) 119 (48.8) 1.4 (0.9, 2.2) 1.1 (0.6, 2.0) 1.7 (0.9, 3.5)
GG 77 (23.2) 68 (27.9) 1.6 (1.0, 2.6) 2.8 (1.2, 6.5) 1.6 (0.8, 3.3)
rs11227332
AA 224 (76.7) 162 (69.2) ref ref ref
AG 61 (20.9) 58 (24.8) 1.3 (0.9, 2.0) 1.3 (0.7, 2.4) 1.6 (0.8, 3.0)
GG 7 (2.4) 14 (6.0) 2.8 (1.1, 7.0) 5.1 (1.3, 20.2) § 2.8 (0.6, 14.4)
rs665306
CC 98 (30.1) 57 (23.7) ref ref ref
CT 151 (46.3) 117 (48.6) 1.3 (0.9, 2.0) 1.0 (0.6, 1.9) 1.9 (0.9, 3.8)
TT 77 (23.6) 67 (27.8) 1.5 (0.9, 2.4) 2.3 (1.0, 5.2) 1.7 (0.8, 3.5)
rs667555
GG 96 (30.1) 55 (23.1) Ref Ref ref
GT 148 (46.4) 122 (51.3) 1.4 (0.9, 2.2) 1.1 (0.6, 2.0) 1.9 (0.9, 4.0)
TT 75 (23.5) 61 (25.6) 1.4 (0.9, 2.3) 2.2 (0.9, 5.5) 1.6 (0.7, 3.4)
OR: Odds Ratio; 95% CI: Wald 95% Confidence Interval;
§: The smallest cell n = 3, Fisher Exact p = 0.01.Publish with BioMed Central    and   every 
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NTDs, these polymorphisms could clarify the complex
mechanism of genetic susceptibility underlying the risk
for NTDs. Further studies of these variations using cellular
experiments could potentially provide an in-depth view of
the mechanism of our observations.
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